This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Innoviva to Attend Investor Conferences
Business investor conference

Innoviva to Attend Investor Conferences

Analysis based on 6 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Innoviva's participation in these investor conferences could lead to increased investor awareness and potentially a positive impact on its stock price. The events provide a platform for Innoviva to showcase its diversified biopharmaceutical portfolio and strategic investments.

Biotechnology Pharmaceuticals
Event Summary

Innoviva, a diversified biopharmaceutical company, announced its participation in two upcoming investor conferences in June 2026. Management will engage in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, and hold 1x1 meetings at the BTIG Infectious Disease Day on June 16, 2026. These events offer Innoviva an opportunity to communicate its business strategy, royalty portfolio, and critical care and infectious disease platform (Innoviva Specialty Therapeutics) to a broader investor audience. Innoviva's portfolio includes respiratory assets partnered with GSK plc and licensed products like ZEVTERA from Basilea Pharmaceutica, and NUZOLVENCE, which was approved by the United States — Food and Drug Administration.

Entities Involved
stock
Innoviva
Innoviva will participate in two investor conferences, providing an opportunity to communicate with investors and potentially increase its visibility and investor interest.
Importance 100.0 Sentiment 10.0
priv
BTIG
BTIG is hosting the Infectious Disease Day, where Innoviva will participate in 1x1 meetings.
Importance 40.0 Sentiment 0.0
stock
Goldman Sachs
Goldman Sachs is hosting the 47th Annual Global Healthcare Conference, where Innoviva will participate in a fireside chat.
Importance 40.0 Sentiment 0.0
stock
GSK plc
GSK plc is a partner of Innoviva, from whom Innoviva receives royalties on sales of respiratory assets.
Importance 20.0 Sentiment 0.0
stock
Basilea Pharmaceutica
Basilea Pharmaceutica is the licensor of ZEVTERA to Innoviva.
Importance 10.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration approved NUZOLVENCE, one of Innoviva's products.
Importance 5.0 Sentiment 0.0
Relationships
Goldman Sachs related ↔ United States — Food and Drug Administration
GSK plc related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.